Home Stem Cells & Wnt Wnt/beta-catenin

Wnt/beta-catenin Activators

Cat.No. Product Name Information Product Use Citations Product Validations
S8178 BML-284 Hydrochloride (Wnt agonist 1, AMBMP) BML-284 (Wnt agonist 1) is a cell permeable Wnt signaling pathway activator, which induces β-catenin- and TCF-dependent transcriptional activity with EC50 of 0.7 μM.
EMBO Mol Med, 2025, 17(7):1794-1824
Mol Psychiatry, 2025, 30(12):5731-5748
Oncol Rep, 2025, 53(1)7
Verified customer review of BML-284 Hydrochloride (Wnt agonist 1, AMBMP)
S3630 Methyl Vanillate Methyl Vanillate, one of the ingredients in Hovenia dulcis Thunb, activates the Wnt/β-catenin pathway and induces osteoblast differentiation in vitro.
Sci Rep, 2022, 12(1):7
E4800 BML-284 BML-284 (Wnt Agonist) is a potent and cell-permeable activator of Wnt signaling that induces TCF-dependent transcriptional activity with an EC50 value of 0.7 µM. This compound also acts as an agonist of β-catenin that effectively activates direct Wnt-β-catenin signaling to induce adipocyte dedifferentiation while circumventing the apoptotic effect in the hypertonic treatment.
S1263 CHIR-99021 (Laduviglusib) Laduviglusib (CHIR-99021, CT99021) is a GSK-3α and GSK-3β inhibitor with IC50 values of 10 nM and 6.7 nM, respectively. It does not exhibit cross-reactivity against cyclin-dependent kinases (CDKs) and shows a 350-fold selectivity toward GSK-3β compared to CDKs. This compound functions as a Wnt/β-catenin activator and induces autophagy.
The Kaohsiung Journal of Medical Sciences, September 12, 2025, e70103
Journal of the American Heart Association, October 2, 2017, e005295
The American Journal of Sports Medicine, February 24, 2025, 1184-1194
Verified customer review of CHIR-99021 (Laduviglusib)
S2924 Laduviglusib (CHIR-99021) Hydrochloride Laduviglusib (CHIR-99021; CT99021) HCl is hydrochloride of CHIR-99021, which is a GSK-3α/β inhibitor with IC50 of 10 nM/6.7 nM; CHIR-99021 shows greater than 500-fold selectivity for GSK-3 versus its closest homologs Cdc2 and ERK2. CHIR-99021 is a potent pharmacological activators of the Wnt/beta-catenin signaling pathway. CHIR-99021 significantly rescues light-induced autophagy and augments GR, RORα and autophagy-related proteins.
Circulation Research, September 08, 2023, 772-788
Blood, November 28, 2019, 1983-1995
Commun Biol, 2026, 10.1038/s42003-026-09838-x
Verified customer review of Laduviglusib (CHIR-99021) Hydrochloride
S7954 CP21R7 CP21R7 is a potent and selective GSK-3β inhibitor that can potently activate canonical Wnt signalling.
Am J Transl Res, 2025, 17(10):8060-8075
J Nanobiotechnology, 2024, 22(1):373
iScience, 2024, 27(10):110862
S7421 CGP 57380 CGP 57380 is a potent MNK1 inhibitor with IC50 of 2.2 μM, exhibiting no inhibitory activity on p38, JNK1, ERK1 and -2, PKC, or c-Src-like kinases. This compound upregulates β-catenin and potentiates radiation-induced apoptosis.
Journal of Medicinal Chemistry, September 13, 2021, 13719-13735
Journal of Cancer, January 1, 2020, 990-996
Journal of Cancer, January 01, 2020, 990-996
Verified customer review of CGP 57380
S7914 ISX-9 (Isoxazole 9) Isoxazole 9 (Isx-9) is a synthetic promotor of adult neurogenesis by triggering neuronal differentiation of adult neural stem/precursor cells (NSPCs). Isoxazole 9 (Isx-9) activates multiple pathways including TGF-β induced epithelial–mesenchymal transition (EMT) signaling, canonical and non-canonical Wnt signaling at different stages of cardiac differentiation.
iScience, 2025, 28(3):112015
Front Cell Dev Biol, 2025, 13:1513163
Cell Regen, 2025, 14(1):18
S3223 L-Quebrachitol L-Quebrachitol (L-QCT), a natural product isolated from many plants, promotes proliferation and cell DNA synthesis. This compound upregulates bone morphogenetic protein-2 (BMP-2) and runt-related transcription factor-2 (Runx2) and regulatory genes associated with mitogen-activated protein kinase (MAPK) and Wnt/β-catenin signaling pathway, while down-regulating the receptor activator of the nuclear factor-κB(NF-κB) ligand (RANKL) mRNA level.
E0072 Indirubin-3′-oxime Indirubin-3′-oxime (IDR3O, I3O) is an indirubin analogue that shows favorable inhibitory activity targeting GSK-3β and CDKs. This compound also inhibits JNKs with IC50s of 0.8 μM, 1.4 μM, and 1.0 μM for JNK1, JNK2, and JNK3, respectively. It activates Wnt/β-catenin signaling and inhibits adipocyte differentiation and obesity.
S6085 KY19382 (A3051) KY19382 (A3051) is a Wnt/β-catenin signalling activator through inhibitory effects on both CXXC5–DVL interaction and GSK3β activity with IC50s of 19 nM and 10 nM, respectively.